Gene: RALGAPB
Official Full Name: Ral GTPase activating protein non-catalytic subunit betaprovided by HGNC
Gene Summary: Enables protein heterodimerization activity. Predicted to be involved in Ral protein signal transduction and activation of GTPase activity. Predicted to act upstream of or within regulation of exocyst localization and regulation of protein localization. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO08928 | RALGAPB Knockout cell line (HeLa) | Human | RALGAPB | 1:3~1:6 | Negative | Online Inquiry |
KO08929 | RALGAPB Knockout cell line (HCT 116) | Human | RALGAPB | 1:2~1:4 | Negative | Online Inquiry |
KO08930 | RALGAPB Knockout cell line (HEK293) | Human | RALGAPB | 1:3~1:6 | Negative | Online Inquiry |
KO08931 | RALGAPB Knockout cell line (A549) | Human | RALGAPB | 1:3~1:4 | Negative | Online Inquiry |
RALGAPB Gene Knockout Cell Lines are specialized cell lines engineered to facilitate the study of the RALGAPB gene's function in various biological processes. By employing CRISPR-Cas9 gene editing technology, these cell lines have been developed to eliminate the RALGAPB gene, allowing researchers to assess its role in cellular signaling pathways, adhesion, and migration. This knockout model serves as a powerful tool for elucidating the mechanisms through which RALGAPB contributes to physiological and pathological conditions, including cancer progression and neurodevelopmental disorders.
The primary mechanism of action of RALGAPB involves the regulation of small GTPases, specifically Rho and Rac, which play critical roles in the modulation of cytoskeletal dynamics and cell motility. By studying these knockout cell lines, researchers gain insights into how the absence of RALGAPB affects these signaling pathways, contributing to our understanding of cellular communication, proliferation, and differentiation.
In the scientific realm, RALGAPB Gene Knockout Cell Lines are invaluable for both research and clinical applications. They are used extensively in the exploration of disease mechanisms and the development of therapeutic strategies, particularly in cancer research where the dysregulation of signaling pathways is prevalent. The ability to observe the cellular behavior in the absence of RALGAPB provides a unique opportunity for high-throughput screening of potential drug candidates and for investigating novel therapeutic targets.
One of the key advantages of our RALGAPB Gene Knockout Cell Lines over alternatives is their validated genetic background and the rigorous methodology employed in their development. Unlike conventional knockout models that may exhibit variable results, these cell lines have undergone extensive characterization to ensure consistent performance in various experimental conditions. This reliability not only enhances experimental reproducibility but also accelerates the pace of research outcomes.
For researchers and clinicians alike, the RALGAPB Gene Knockout Cell Lines represent an essential resource for advancing our understanding of gene function and its implications in health and disease. Our company specializes in high-quality biological products that are meticulously designed to meet the evolving needs of the scientific community. With our commitment to innovation and excellence, we provide tools that empower researchers in their quest to uncover new biological insights.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.